MPM Capital, the largest venture capital investor dedicated solely to
healthcare, announced today that Robert Millman, J.D., and Elizabeth
Stoner, M.D., have joined MPM as Executive Partners. Both will be based
in MPM’s Boston office.
“Robert and Liz bring to MPM expertise that
further enhances the capabilities of our senior investment team,”
said Ansbert Gadicke, Founding General Partner. “Our
record of successful investing is predicated on an internal team that
can be leveraged throughout the investment cycle, from due diligence to
the operations and management of specific company functions rather that
going outside for specialized resources. In addition to successful CEOs,
investment bankers, and clinical development specialists, with Robert
and Liz, we have added expertise in intellectual property and a global
perspective on the clinical operations/management of big pharma
pipelines. We expect that both individuals will make significant
contributions across the spectrum of our investing activities.”
Robert Millman brings to MPM 18 years of experience in creating and
managing intellectual property and patent estates for biotechnology as
well as drug discovery and development companies. Most recently, he was
the Chief IP Counsel for Alnylam Pharmaceuticals Inc., where he
developed the leading intellectual property portfolio in RNAi
therapeutics. Prior to Alnylam, for three years he served as the Chief
IP Counsel at Infinity Pharmaceuticals, Inc., a company focused on small
molecule discovery. From 1999 to 2002, Mr. Millman was Chief IP Counsel
at Celera Genomics, where he developed and implemented an IP protection
plan during the race to sequence the human genome. Mr. Millman has
previously served as Patent Counsel at Millennium Pharmaceuticals, Inc.,
and earlier in his career he held an associate position at Morrison and
Foerster LLP and a patent agent/specialist position at Sterne, Kessler
Goldstein and Fox, LLP. Mr. Millman received his J.D. degree from the
Washington College of Law at The American University, an M.S. degree in
Genetics from Washington State University, and a B.S. degree in
Biochemistry from the University of California, Riverside.
Dr. Elizabeth Stoner joined MPM following a 22-year career at Merck
Research Laboratories. At the time of her retirement from Merck, Dr.
Stoner was Senior Vice President of Global Clinical Development
Operations with responsibility for the company’s
clinical development activities in more than 40 countries. She also
oversaw the clinical development activities of Merck’s
Japanese partner Banyu, led the clinical development for the
Merck/Schering-Plough Joint Venture for Zetia/Vytorin, and played a
critical leadership role in Merck’s efforts to
transform its worldwide clinical development operations. Earlier in her
career at Merck, Dr. Stoner led the Proscar clinical development program
from inception, establishing Merck as a leader in the field of prostate
disease. As Endocrine Therapeutic Head, Dr. Stoner’s
responsibilities included all steroid and lipid metabolism, as well as
the growth hormone secretagogue, clinical research programs. Prior to
her position at Merck, she was an Assistant Professor of Pediatrics at
Cornell University Medical College. Dr. Stoner received a B.S. in
Chemistry from Ottawa University, KS, an M.S. in Chemistry from the
State University of New York at Stony Brook, and an M.D. from Albert
Einstein College of Medicine.
About MPM
MPM Capital is the world's largest dedicated investor in life sciences.
With committed capital under management in excess of $2.5 billion, MPM
Capital is uniquely structured to invest globally in healthcare
innovation. In addition to its MPM BioVentures family of venture capital
funds, MPM Capital invests in the public markets through its MPM
BioEquities hedge fund. Primarily in biotechnology and
biopharmaceuticals, but also in medical devices, MPM Capital has
seamlessly integrated its private and public platforms to focus on
innovation in healthcare and, thereby, delivering exceptional returns to
investors. MPM Capital is the manager of the MPM BioVentures and MPM
BioEquities family of funds - two distinctly different but highly
complementary investment platforms.
|